Skip to main content

Table 1 Patient characteristics

From: A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

Characteristic Patients
Total (n = 27) 100 mg (n = 9) 250 mg (n = 9) 500 mg (n = 9)
No. % No. % No. % No. %
Age, years
 Mean 51 51 53 49
 Range 28–67 40–67 36–64 28–63
ECOG performance status
 0 18 66.7 8 88.9 5 55.6 5 55.6
 1 9 33.3 1 11.1 4 44.4 4 44.4
Level of HER2/neu overexpression
 2+ 8 29.6 3 33.3 2 22.2 3 33.3
 3+ 19 70.4 6 66.7 7 77.8 6 66.7
Receptor status
 Estrogen receptor-positive (n = 26) 14 53.8 4 44.4 3 37.5 7 77.7
 Progesterone receptor-positive (n = 26) 9 34.6 3 33.3 2 25.0 4 44.4
Menopausal status
 Premenopausal 7 25.9 1 11.1 3 33.3 3 33.3
 Postmenopausal 18 66.7 6 66.7 6 66.7 6 66.7
 Perimenopausal 2 7.4 2 22.2 0   0  
No. of metastatic sites
 1 10 37.0 2 22.2 4 44.4 4 44.4
 2 6 22.2 2 22.2 2 22.2 2 22.2
 ≥3 11 40.7 5 55.6 3 33.3 3 33.3
Dominant site of metastasis
 Bone 15 55.6 5 55.6 4 44.4 6 66.7
 Lymph node 12 44.4 5 55.6 4 44.4 3 33.3
 Viscera 10 37.0 5 55.6 2 22.2 3 33.3
No. of prior chemotherapy regimens for metastatic disease
 None 8 29.6 0   3 33.3 5 55.6
 1 14 51.9 5 55.6 6 66.7 3 33.3
 2 5 18.5 4 44.4 0   1 11.1
 Prior hormonal therapy 13 48.1 8 88.9 2 22.2 3 33.3
 Prior radiotherapy 15 55.6 4 44.4 6 66.7 5 55.6